Vertex Receives TGA Approval for ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class CFTR Modulator for the Treatment of Cystic Fibrosis
By API User
ALYFTREK® is now registered by the TGA for Australians with cystic fibrosis aged 6 years and older with at least one responsive CFTR mutation– Approximately 3,200 Australians may now be eligible for this next-in-class treatment for cystic fibrosis1 – SYDNEY, 20 November 2025 – Vertex Pharmaceuticals today announced that the Therapeutic Goods Administration … Continued